BRCA2 and ovarian cancer: This result thus suggests that BRCA2 status alone is not a reliable indicator of chemotherapy sensitivity and that transcriptional mis-regulation may instead be a key component in the development of drug resistance in ovarian cancer, as previously suggested [4, 27–29].